Clinical trials: Non-small Cell Lung Cancer Stage II
Non-small Cell Lung Cancer
Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC)
The rationale of phase II study of biweekly docetaxel and cisplatin in patients with unresectable NSCLC are follows: First, the optimal dose and schedule of combination with docetaxel and cisplatin are still controversial (3…
- Trial name
- NCT00995761
- Testing
- Docetaxel and Cisplatin
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Gyeongsang National University Hospital
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
This phase I/II trial studies the best dose and effect of pimasertib in combination with bintrafusp alfa in treating patients with cancer that has spread to the brain (brain metastases).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma
- Trial name
- NCT04789668
- Testing
- Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Neoplasms, Pheochromocytoma
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
Background: The drug R935788 (fostamatanib disodium) is a kinase inhibitor (i.e., it interferes with cell communication and growth and may prevent tumor growth).
- Conditions
- Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00923481
- Testing
- Fostamatinib disodium
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
This study will evaluate the combination of bevacizumab and erlotinib in elderly patients with advanced non-small cell lung cancer.
- Trial name
- NSCLC (NCT00553800)
- Testing
- bevacizumab, Erlotinib
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Fox Chase Cancer Center
Lung Cancer, Small Cell
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
This is a Phase II, randomized, open-label, multi-center study in advanced (Stage IVA and IVB subjects per the International Association for the Study of Lung Cancer (IASLC) 2009 Lung cancer staging schema) non-squamous NSCLC…
- Trial name
- NCT01313663
- Testing
- pazopanib, pemetrexed
- Where
- 25 sites in United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage I
SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects
This is a single arm, multi-centre, phase II open label study of nivolumab with stereotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer.
- Trial name
- STILE (NCT03383302)
- Testing
- Stereotactic body radiotherapy, Nivolumab
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Carcinoma, Non-Small-Cell Lung
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor…
- Trial name
- NCT02414139
- Testing
- Capmatinib
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 373 people
- Sponsor
- Novartis Pharmaceuticals
Adenocarcinoma of the Lung, Large Cell Lung Cancer
S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
This randomized phase II trial studies how well pemetrexed disodium with or without crizotinib works in treating patients with stage IV non-small cell lung cancer that has progressed after crizotinib.
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT02134912
- Testing
- crizotinib, pemetrexed disodium, laboratory biomarker analysis
- Where
- 167 sites in United States
- Volunteers
- 1 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC
Primary Objective: To determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced NSCLC who have failed at least one prior chemotherapy regimen.
- Trial name
- NCT00410189
- Testing
- ZD6474
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
The goal of this clinical research study is to learn about the safety and effectiveness of OSI-774 when combined with standard chemotherapy (carboplatin and paclitaxel) before surgery in the treatment of non-small cell lung…
- Trial name
- NCT00063258
- Testing
- Tarceva (OSI-774), Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Non-Small Cell Lung Cancer
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern…
- Trial name
- NCT00085839
- Testing
- Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
- Where
- 19 sites in United States
- Volunteers
- 103 people
- Sponsor
- OSI Pharmaceuticals
Non-Small-Cell Lung Cancer
Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer
This study is designed to evaluate Pemetrexed and Gemcitabine Day 1 followed by Gemcitabine Day 8 every 21 days (Arm A) and Pemetrexed and Gemcitabine Day 1 every 14 days (Arm B) in patients with NSCLC.
- Trial name
- NCT00383331
- Testing
- Pemetrexed, Gemcitabine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Eli Lilly and Company
Recurrent Small-cell Lung Cancer (SCLC), Lung Cancer, Small Cell
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells…
- Trial name
- NCT00698516
- Testing
- Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Adenocarcinoma, Non-small Cell Lung Cancer
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
The purpose of this trial is to figure out what effects (good or bad) the investigational drug agent called Tarceva (erlotinib; OSI-774) has on women with previously untreated adenocarcinoma.
- Trial name
- NCT00137839
- Testing
- Erlotinib
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pasi A. Janne, MD, PhD
Lung Cancer, Metastatic Cancer
Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
RATIONALE: Cryotherapy kills tumor cells by freezing them. This may be an effective treatment for primary lung cancer or lung metastases that cannot be removed by surgery.
- Trial name
- NCT00303901
- Testing
- cryosurgery, positron emission tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Carcinoma, Non-Small-Cell Lung
BIO 300 Non-Small Cell Lung Cancer Study
The purpose of this study is to determine the safety and effectiveness of BIO 300 Oral Suspension when used in combination with standard dose radiation therapy and chemotherapy in patients with non-small cell lung cancer.
- Trial name
- NSCLC (NCT02567799)
- Testing
- BIO 300 Oral Suspension, Paclitaxel, Carboplatin
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Humanetics Corporation
Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain
Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases
This is an open-label phase II clinical trial designed to allow a preliminary assessment of the efficacy and safety of cabozantinib in unselected Non-Small Cell Lung Cancer (NSCLC) patients with metastases to the brain and in the…
- Trial name
- NCT02132598
- Testing
- cabozantinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Liza Villaruz, MD
Non-Small Cell Lung Cancer Metastatic
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
This is a Phase II, open label, randomized study of durvalumab in combination with pemetrexed and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell lung cancer.
- Trial name
- STAGGER (NCT04163432)
- Testing
- Durvalumab, Pemetrexed, Carboplatin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Utah
Carcinoma, Non-Small-Cell Lung
Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients
The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by the RECIST criteria, in patients with advanced NSCLC…
- Trial name
- NCT00730925
- Testing
- BIBW2992, BIBW2992 + paclitaxel
- Where
- 7 sites in Belgium, Spain
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim